Patent: 7,879,816
✉ Email this page to a colleague
Summary for Patent: 7,879,816
Title: | Methods of treating cancer and other conditions or disease states using LFMAU and LDT |
Abstract: | The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R.sup.1 and R.sup.2 are independently H, an acyl group, a C.sub.1-C.sub.20 alkyl or ether group, a phosphate, diphosphate, triphosphate or a phosphodiester group, a (A) or (B) group; Where Nu is a radical of a biologically active compound such as an anticancer, antiviral or antihyperproliferative compound such that an amino group or hydroxyl group from said biologically active agent forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; each R.sup.8 is independently H, or a C.sub.1-C.sub.20 alkyl or ether group, preferably a C.sub.1-C.sub.12 alkyl group; k is 0-12, preferably, 0-2; and pharmaceutically acceptable salts thereof. ##STR00001## |
Inventor(s): | Cheng; Yung-chi (Woodbridge, CT) |
Assignee: | Yale University (New Haven, CT) |
Application Number: | 11/921,194 |
Patent Claims: | see list of patent claims |
Details for Patent 7,879,816
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2025-06-07 |
Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2025-06-07 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2025-06-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |